Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Eduardo MyslerYoshiya TanakaArthur KavanaughDaniel AletahaPeter C TaylorIn-Ho SongTim ShawYanna SongRyan DeMasiMira AliRoy FleischmannPublished in: Rheumatology (Oxford, England) (2022)
ClinicalTrials.gov, https://clinicaltrials.gov, NCT02629159.